SMAD | Jotup

GeoClerk Launches Canada Expansion at PDAC 2024

Retrieved on:

Thursday, February 15, 2024

Archive, Mineral, TSX, Database, ARIS, PDAC, SMAD

The expansion features databases containing all the publicly available archives from Ontario (GeologyOntario), Quebec (SIGÉOM), British Columbia (ARIS) and Saskatchewan (SMAD), with further provincial and territorial databases planned later in 2024.

Key Points:

The expansion features databases containing all the publicly available archives from Ontario (GeologyOntario), Quebec (SIGÉOM), British Columbia (ARIS) and Saskatchewan (SMAD), with further provincial and territorial databases planned later in 2024.
With this addition, GeoClerk users can now easily access valuable geological information in historical reports, exploration updates, annual company reports, NI43-101s and other filings across Canada, all in one place.
GeoClerk is proud to be a technological pioneer in the resources sector, and these latest provincial database additions, make GeoClerk one of the fastest and most comprehensive resources for companies exploring in Canada.
"We are thrilled to debut GeoClerk at PDAC in 2024 with this expansion into Canada.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on:

Monday, May 22, 2023

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points:

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

Retrieved on:

Monday, April 17, 2023

PK, AACR, Phosphorylation, SMAD, TGF beta 1, NK, Doctor of Philosophy, Transforming growth factor beta, Cancer, TME, Mouse, Poster, Neoplasm, Corbus, TGI, M1, Breast cancer, Vaccine

NORWOOD, Mass., April 17, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.

Key Points:

NORWOOD, Mass., April 17, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.
In addition, the impact on TGFβ pathway signaling and tumor immune cell population are also presented.
Tumor growth was evaluated in mice bearing orthotopically implanted murine breast cancer EMT6 or colon cancer MC38 and treated with CRB-601.
Together this data reinforces the potential of this new approach in blocking activation of TGFb locally in the TME."

Agilent Showcases Comprehensive Cancer Portfolio Solutions at AACR 2023

Retrieved on:

Friday, April 14, 2023

Biotechnology, Genetics, Health, Oncology, DNA, Partnership, AACR, Therapy, CGP, NGS, Cancer, SMAD, Woman, Research, Genomics, RNA, Incidence, Assay, Algorithm, Cell, Cell Signaling Technology, Diagnosis, CDX, Death, NYSE, Medical imaging, Agilent Technologies

Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.

Key Points:

Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023.
An estimated 41 out of 100 men and 39 out of 100 women will potentially develop cancer during their lifetime1.
“Cancer remains a significant area of strategic focus for Agilent.
AACR poster sessions will include multiple Agilent research posters and more than 50 additional customer posters featuring Agilent instruments and solutions.

Traction Uranium Completes the First Drill Hole at Key Lake South and Begins Drilling the Second Target Located Directly Above the “Radioactive Swamp”

Retrieved on:

Tuesday, March 14, 2023

Diamond, Anomaly, Geological survey, Traction, Assessment, SRC, Uranium, SMAD, IPCC Fourth Assessment Report, FRA, OTC, NTS, Exploration diamond drilling, News, Ford, TRAC, CSE, Oil, Rare-earth element

Phase 1 diamond drilling is planned for 10 high priority targets totaling approximately 2,000 metres (see Figure 2).

Key Points:

Phase 1 diamond drilling is planned for 10 high priority targets totaling approximately 2,000 metres (see Figure 2).
The previously unknown radioactive anomalies discovered by Traction’s exploration team during the ground program of 2022 are of particular interest.
In addition, with the ground presently frozen, the “radioactive swamp” is now accessible which is another high priority drill target for the Company’s team.
Drill crews are currently mobilizing the drill shack (see Figure 3) to target KLS23-002 to commence drilling beneath the radioactive swamp this week.

Traction Uranium Commences Key Lake South (KLS) Phase 1 Diamond Drill Program

Retrieved on:

Tuesday, March 7, 2023

OTC, SRC, Traction, TRAC, Uranium, CSE, IPCC Fourth Assessment Report, SMAD, FRA, NTS, Geological survey, KLS, Ford, News, Assessment, Rare-earth element, Oil, Cobalt

The winter 2023 KLS diamond drill program will follow up on the “radioactive black soil” that had assayed high grade uranium mineralization (0.93 wt.

Key Points:

The winter 2023 KLS diamond drill program will follow up on the “radioactive black soil” that had assayed high grade uranium mineralization (0.93 wt.
Phase 1 diamond drilling is planned for 10 high priority targets totaling approximately 2,000 metres (see Figure 2).
The previously unknown radioactive anomalies discovered by Traction’s exploration team during the ground program of 2022 are of particular interest.
Drill crews are currently mobilizing equipment to the first drill target to commence coring this week (see Figure 3).

Sony Electronics Returns to NAB Show In-Person and Virtually with Updates Focused on Imaging, IP, Cloud and Visualization Workflows

Retrieved on:

Sunday, April 24, 2022

LAS VEGAS, April 24, 2022 /PRNewswire/ -- At NAB Show 2022, April 24-27 at the Las Vegas Convention Center, Sony Electronics is proudly unveiling and showcasing a broad range of products and services, to empower broadcast, to cinematic and live event content creation. These innovations align with leading industry trends in the Imaging, Internet Protocol (IP), Cloud and Visualization realm. Sony will be exhibiting in booth #C10901 and virtually at https://pro.sony/nab.

Key Points:

Sony Returns to NAB In-Person and Virtually with Updates Focused on Imaging, IP, Cloud and Visualization Workflows
"The last few years have redefined the world as well as our industry," saidTheresa Alesso, President, Imaging Products & Solutions Americas, Sony Electronics.
As the industry standard, users continue to seek exceptional camera choices from Sony, at every level, capability and price.
Headquartered in San Diego, California, Sony Electronics is a leader in electronics for the consumer and professional markets.
Sony Electronics creates products that innovate and inspire generations, such as the award-winning Alpha Interchangeable Lens Cameras and revolutionary high-resolution audio products.

ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS

Retrieved on:

Tuesday, April 6, 2021

Branches of biology, Transcription factors, Biology, PDAC, Pancreatic cancer, KRAS, SMAD, Mothers against decapentaplegic homolog 4, Anatomical pathology, Oncology, Circulating tumor cell

A peer-reviewed article, published in the journal Cancer Letters ( click to access article ), describes a Johns Hopkins Medicine study that validated PDAC CTC detection by a targeted scNGS method of three driver mutant genes (KRAS/TP53/SMAD4) with ISET-enriched CTC of PDAC patients.

Key Points:

A peer-reviewed article, published in the journal Cancer Letters ( click to access article ), describes a Johns Hopkins Medicine study that validated PDAC CTC detection by a targeted scNGS method of three driver mutant genes (KRAS/TP53/SMAD4) with ISET-enriched CTC of PDAC patients.
Blood samples from patients with late-stage and metastatic PDAC, showed CTCs with SNVs of KRAS/TP53/SMAD4 and the positive confirmation of immuno-fluorescent staining with Pan-CK/Vimentin/CD45.
The validation of this innovative and affordable targeted digital scNGS analysis of mutated PDAC CTC enriched with ISET technology provides the scientific community with a reliable PDAC CTC detection workflow.
Although larger cohort studies are needed, this is an opening to a personalized medicine approach in pancreatic cancer patients targeting on CTCs."

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

Retrieved on:

Friday, September 11, 2020

Branches of biology, Proteins, Protein structure, Protein families, Activin and inhibin, Mammal reproductive system, Forward-looking statement, Cell signaling, SMAD, Activin receptor

KER-012 is a modified activin receptor type II ligand trap designed to bind to and inhibit activins and SMAD 2/3 signaling.

Key Points:

KER-012 is a modified activin receptor type II ligand trap designed to bind to and inhibit activins and SMAD 2/3 signaling.
Words such as "anticipates," "believes," "expects," "intends," plans, potential, "projects, would and "future" or similar expressions are intended to identify forward-looking statements.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
All forward-looking statements contained in this press release speak only as of the date on which they were made.

TGF Beta Receptor Type 1 - 2020 Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on:

Friday, April 3, 2020

Health, Pharmaceutical, Branches of biology, Proteins, Transforming growth factor beta, Health sciences, Mechanism of action, Transcription factors, Signal transduction, SMAD, TGF beta Activation

The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
TGF Beta Receptor Type 1 pipeline Target constitutes close to 17 molecules.
This report outlays comprehensive information on the TGF Beta Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.